No Data
BEIGENE (06160.HK) will release its Earnings Reports on May 7.
$BEIGENE (06160.HK)$ will release its Earnings Reports on May 7th, investors please pay attention. How was the performance previously? $BEIGENE (06160.HK)$ 2024 Q4 revenue was $1.128 billion, Net income was -$-0.152 billion, and EPS was -$0.11. 2024 Q1 revenue was $0.752 billion, Net income was -$-0.251 billion, and EPS was -$0.19. Futubull reminds: 1. There are no strict regulations on the accounting year divisions for companies listed on Hong Kong and US stock exchanges, and it is entirely up to the companies to decide. Therefore, each Earnings Reports period can be considered as a business.
Top Gap Ups and Downs on Wednesday: SAN, SBUX, MDLZ and More
US stock movement | BEIGENE (ONC.US) rose over 3% as revenue for 2024 increased by 55% year-on-year.
On Wednesday, BEIGENE (ONC.US) rose over 3%, reaching $259.
BEIGENE (06160) rises by 6.11% after winning the patent dispute in the USA.
Jingwu Financial News | BEIGENE (06160) is fluctuating strongly, as of this report, up 6.11%, at HKD 158.1, with a transaction amount of 0.618 billion HKD. In terms of news, BEIGENE announced that the US Patent and Trademark Office made a final written decision, declaring that Pharmacyclics LLC's rights to US Patent No. 11,672,803, which was challenged by BEIGENE during the post-grant review process, are completely invalid. On November 1, 2023, regarding the patent infringement suit filed by Pharmacyclics against BEIGENE concerning BRUKINSA.
Express News | Beigene Says Pharmacyclics Litigation Is Not Expected to Have Adverse Effect on Co's Production, Operation
Express News | Beigene Says Pharmacyclics Litigation Is Not Having Adverse Effect on Development, Sales of Brukinsa in U.S.
